Carnegie acted as joint global co-ordinator and joint bookrunner in the directed share issue of 746,269 new shares at a subscription price of SEK 335 per share. Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. XVIVO’s solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
October 2021.
Healthcare
Directed share issue in XVIVO Perfusion AB (SE) — SEK 250 million
October 2021